Every funding decision a founder makes reduces to one question: is this risk mine or an investor's? Dilutive funding transfers risk — an investor buys a permanent slice of the outcome and absorbs the downside with you. Non-dilutive funding keeps the risk yours, and you keep the ownership that goes with it. Most founders treat this as a question of availability rather than a decision. It is a decision, and the math is more legible than it looks.
What each one actually is
Dilutive funding means selling ownership: priced equity rounds, SAFEs, convertible notes that eventually convert. You receive capital and give up a percentage of the company, usually along with investor rights — board seats, information rights, protective provisions, liquidation preferences that pay investors first in an exit. It does not get repaid; it gets exited.
Non-dilutive funding is capital you repay. Revenue-based financing, receivables-based funding, merchant cash advances, equipment financing, venture debt, grants, and bank credit all qualify. You take money, repay it over a term, and your cap table is exactly where it was. The obligation is real and dated, which is the tradeoff — it must be serviced from revenue whether or not the month goes well.
The math that founders skip
Founders reliably compare a stated cost of capital against a percentage of equity and conclude equity is cheaper, because the cost is invisible today. Try it against an outcome instead. Sell 15% of your company at a $6M valuation and you receive $900,000. If the company eventually exits at $40M, that 15% was worth $6M — you paid roughly $5.1M for $900,000, spread across the years. Non-dilutive capital of the same size costs a defined amount, paid over months, and is finished. The dilutive route can still be the right one — if the $900,000 is what makes the $40M outcome possible at all, or if the company would not have survived the downside without it. But the honest comparison is cost of capital against the value of what you sold at the outcome you are working toward, not against a number that feels large today.
When dilutive funding is the right call
Equity is the correct instrument when the risk genuinely belongs on an investor: pre-revenue, long R&D cycles, capital-intensive buildouts before any customer exists, or a market where winning requires spending far ahead of revenue and losing means the money is gone. It is also right when the investor brings something the capital does not — distribution, hiring, credibility with enterprise buyers, a network that changes the trajectory. And it is right when the alternative is an obligation your revenue plainly cannot service. Taking repayable capital against revenue that does not exist yet is how companies end up in a debt spiral instead of a down round.
When non-dilutive funding is the right call
Non-dilutive fits when the need is bounded and the revenue is real: bridging enterprise customers who pay net-60 or net-90, hiring against contracted work, funding a marketing or sales push with measurable payback, covering infrastructure or compute costs, or reaching the next milestone without pricing a round at today's valuation. That last one matters more than it used to. Founders whose last round was priced high often face a market that would price them lower now, and a down round carries costs beyond the percentage — signaling, anti-dilution mechanics, team morale. Bridging to better numbers on non-dilutive capital preserves the option to raise later at a valuation you would accept.
The test to run before deciding
Three questions get you most of the way. First: is this need bounded and dated, or open-ended? Bounded needs suit repayable capital; open-ended runway suits equity. Second: can current revenue service the payment through a bad quarter, not just a good one? Model the remittance against your worst recent month, not your average — if it only works when things go well, it does not work. Third: what is the money actually for? Capital deployed into something with measurable payback — a contract, a receivable, a sales motion with known conversion — justifies repayable financing. Capital funding discovery, research, or hope belongs on equity.
They are not mutually exclusive
The most capital-efficient companies use both deliberately: equity for the risk that genuinely belongs to investors, non-dilutive capital for the working capital and growth needs that do not. Raising a round to cover a receivables gap is expensive in a way that compounds over the company's entire life; funding that gap non-dilutively and reserving equity for the strategic bet is the version founders wish they had run three years earlier.
Y Millennial Funding is a direct funder providing revenue-based, non-dilutive capital to companies doing $25,000 or more in monthly revenue — including software, AI and technology services, healthcare, and service businesses. Same-day decisions for eligible applications. Not all applicants qualify.